Latest Security News

Argo Global Listed Infrastructure Limited has announced the renewal of its on-market buy-back facility, allowing the repurchase of up to 8.9 million ordinary shares over the next year starting September 2025.

Camplify Holdings Limited reported a 12.3% revenue decline to $42.1 million and a near doubling of net loss to $15.8 million in FY25, reflecting a year of strategic transformation including the launch of its MyWay protection product and completion of European platform integration.

Core Lithium Ltd has launched a non-underwritten equity raising to secure approximately A$60 million, aiming to advance its Finniss Lithium Project to a final investment decision. The capital raise includes a two-tranche placement and a share purchase plan, supporting operational readiness and strategic funding efforts.

Core Lithium has successfully raised $50 million through a two-tranche institutional placement, complemented by a $10 million Share Purchase Plan, to accelerate its Finniss Lithium Project towards a Final Investment Decision.

Helix Resources Limited’s HLXOA securities have been suspended from trading pending regulatory compliance, raising questions about the company’s immediate outlook.

Mastermyne Group has received a Letter of Intent to extend its underground mining contracts with Anglo American Steelmaking Coal, potentially adding $31 million in revenue through April 2026.

Orcoda Limited faced a challenging FY25 due to delayed projects from a key customer but is poised for recovery with new contracts and growth in recurring revenue. The company’s strategic diversification and AI-powered solutions underpin a confident outlook for FY26.

Gladiator Resources has successfully closed an oversubscribed placement raising $1.18 million to advance its strategic focus on rare earth elements in the United States, signaling strong investor confidence.

Cyprium Metals has secured A$80 million through a placement and entitlement offer to fund the restart of its Nifty Copper Complex and reduce existing debt, backed by strong institutional support.

InhaleRx has secured ethics approval to begin a Phase 1 clinical trial of IRX-616a, a synthetic cannabidiol inhaler aimed at providing fast relief for panic disorder. The fully funded study will assess safety and pharmacokinetics in healthy volunteers.

Anagenics has delivered a significant financial turnaround in FY25, driven by a strategic restructure, exiting loss-making operations, and securing new royalty agreements. Despite a revenue dip, the company improved profitability and cash flow, positioning itself for sustainable growth.

FINEOS Corporation delivered solid first-half results with revenue growth and improved profitability, while navigating currency challenges that temper full-year guidance.